We are a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. We are committed to improving patientsโ lives worldwide by targeting diseases with high unmet needs. Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to Phase 4 programs in immunology, oncology, and other indications. Our first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.
Year founded1999
Served areaWorldwide
HeadquartersGeneraal De Wittelaan L11 A3, 2800 Mechelen, Antwerpen โ Belgium
65,835,511
IPOMay 6, 2005
Stock exchange(s)Euronext Brussels